GlassScriptPhysician profile
Edward J Fricker
NPI 1316933823
$3,676.13
in general payments reported to CMS, 2019-2025
23 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2020: $191 · 2021: $88.19 · 2022: $192 · 2023: $515 · 2024: $1,095 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,033 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,032.94 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,173.08 | 2019-2025 | |
| Madrigal Pharmaceuticals | $564.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $396.42 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $242.99 | 2024-2025 | Voquezna |
| Boston Scientific Corporation | $151.38 | 2021-2024 | |
| Intercept Pharmaceuticals, INC. | $147.19 | 2020-2025 | Ocaliva |
| Janssen Biotech, INC. | $124.40 | 2023-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $118.33 | 2020-2023 | Entyvio |
| Pfizer INC. | $92.39 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $80.80 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $68.18 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $65.86 | 2024-2025 | |
| Celltrion USA INC. | $57.96 | 2025 | Vegzelma |
| Bayer Healthcare Pharmaceuticals INC. | $56.99 | 2022 | |
| Medtronic, INC. | $56.78 | 2025 | Gi Genius |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $54.59 | 2025 | Iqirvo |
| Portola Pharmaceuticals, LLC | $47.57 | 2020 | |
| Redhill Biopharma INC. | $38.79 | 2020 | |
| Evoke Pharma, INC. | $38.03 | 2021-2023 | Gimoti |
| Ferring Pharmaceuticals INC. | $33.73 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $25.62 | 2023 | Sutab |
| Regeneron Healthcare Solutions, INC. | $20.17 | 2025 | Dupixent |
| Pacira Pharmaceuticals Incorporated | $20.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Fricker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.